Should you buy Merck stock now?
Yes, the technical signal for Merck is currently Strong Buy. Merck trades at $145.97 as of Oct 17, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.077 with falling momentum (signal: 0.118); RSI is at 52.2 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $158.28 points to 8.4% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Merck stock?
The average analyst price target for Merck is $158.28. The current price is $145.97, which gives an upside of 8.4%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $142.45 and $174.11.
Is Merck a dividend stock?
Yes, Merck is a dividend stock with a dividend yield of 2.33%. The latest dividend was $0.85 per share. The latest ex-dividend date (traded without the dividend) was Sep 15, 2026. The payout ratio is 105.9%, which is considered high.
When does Merck pay a dividend in 2026?
The next dividend date for Merck has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Sep 15, 2026. The latest dividend was $0.85 per share with an ex-dividend date of Sep 15, 2026. The dividend yield is 2.33%. The payout ratio of 105.9% points to a high dividend relative to earnings.
What is the risk of Merck stock?
Merck is rated as a stock in the risk category Balanced. the annual standard deviation is 29.1%, which classifies the stock as Balanced.
Is Merck overvalued?
Merck is considered fairly valued – the price is close to the analyst price target. Merck has the following valuation ratios: a P/E ratio of 115.6 (highly valued), a P/S ratio of 5.4, a P/B ratio of 8.7. The stock trades close to the analyst price target and is considered fairly valued.
Is Merck overbought?
No, Merck is not overbought. RSI is at 52.2 (neutral zone). The technical indicators show: RSI is at 52.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.2% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Merck earnings report?
Merck reports its next earnings on October 29, 2026. The stock currently trades at $145.97. With a P/E ratio of 115.6, the market will be watching closely whether earnings meet expectations.
Is Merck shorted?
Yes, Merck is shorted with 1.4% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Merck stock?
No, insiders are not buying Merck shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 9 sales. On a net basis, 15,520,037 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 51,261,933 $ sold. Active sellers include Guindo Chirfi, Zachary Jennifer, DeLuca Richard R. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Merck a good stock?
Based on our total score, Merck is rated as a mediocre stock with a total score of 43 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 14/100, Quality: 29/100, Momentum: 86/100. In addition: a dividend of 2.33%. Whether now is the time to buy is a separate question: the technical signal is Strong Buy. Whether Merck is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Merck stock?
The outlook for Merck based on current data: the average analyst price target is $158.28 (+8.4%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Oct 29, 2026, which can move the price; the P/E ratio is 115.6 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Merck stock moving?
Merck is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Merck go?
The average analyst price target for Merck is $158.28, which corresponds to a potential gain of 8.4% from the current price of $145.97. The stock has traded between $79.67 and $156.00 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Merck fall?
The stock has traded as low as $79.67 over the last 52 weeks — that is 45.4% below the current price of $145.97. The biggest decline (drawdown) in the same period was 48.9% from high to low. Within a year, the price typically swings about ±29.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Merck do?
Here is the rewritten description:
Merck & Co. (ticker: MRK) is a large healthcare company. It makes money mainly by developing and selling medicines and vaccines for people, and health products for animals.
On the human health side, the company sells cancer drugs, including... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Merck as an investment.
Did Merck raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Merck. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Merck making money or losing money?
Yes, Merck is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 4.8% — which is modest. At a P/E ratio of 115.6, you currently pay 115.6 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Merck go bankrupt?
The bankruptcy risk of Merck is rated as low. Altman Z2 (a model for assessing financial distress) is 2.92 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 153% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Merck have a lot of debt?
Yes, Merck has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 153%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Merck service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -0.3x, and net debt equals 1.6 years of earnings (EBITDA).
